These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 29771727)

  • 1. Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug-Drug Interactions in Rats.
    Melillo N; Scotcher D; Kenna JG; Green C; Hines CDG; Laitinen I; Hockings PD; Ogungbenro K; Gunwhy ER; Sourbron S; Waterton JC; Schuetz G; Galetin A
    Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining hyperpolarized
    Ohliger MA; von Morze C; Marco-Rius I; Gordon J; Larson PEZ; Bok R; Chen HY; Kurhanewicz J; Vigneron D
    Magn Reson Med; 2017 Jun; 77(6):2356-2363. PubMed ID: 27298073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A model selection framework to quantify microvascular liver function in gadoxetate-enhanced MRI: Application to healthy liver, diseased tissue, and hepatocellular carcinoma.
    Berks M; Little RA; Watson Y; Cheung S; Datta A; O'Connor JPB; Scaramuzza D; Parker GJM
    Magn Reson Med; 2021 Oct; 86(4):1829-1844. PubMed ID: 33973674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mathematical models for biomarker calculation of drug-induced liver injury in humans and experimental models based on gadoxetate enhanced magnetic resonance imaging.
    Karlsson M; Simonsson C; Dahlström N; Cedersund G; Lundberg P
    PLoS One; 2023; 18(1):e0279168. PubMed ID: 36608050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo gadoxetate relaxivities in rat liver tissue and blood at five magnetic field strengths from 1.41 to 7 T.
    Ziemian S; Green C; Sourbron S; Jost G; Schütz G; Hines CDG
    NMR Biomed; 2021 Jan; 34(1):e4401. PubMed ID: 32851735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of imaging to assess the activity of hepatic transporters.
    Hernández Lozano I; Langer O
    Expert Opin Drug Metab Toxicol; 2020 Feb; 16(2):149-164. PubMed ID: 31951754
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of gadoxetate disodium for functional MRI based on its unique molecular mechanism.
    Choi Y; Huh J; Woo DC; Kim KW
    Br J Radiol; 2016; 89(1058):20150666. PubMed ID: 26693795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Troubleshooting Arterial-Phase MR Images of Gadoxetate Disodium-Enhanced Liver.
    Huh J; Kim SY; Yeh BM; Lee SS; Kim KW; Wu EH; Wang ZJ; Zhao LQ; Chang WC
    Korean J Radiol; 2015; 16(6):1207-15. PubMed ID: 26576109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling Gadoxetate Liver Uptake and Efflux Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging Enables Preclinical Quantification of Transporter Drug-Drug Interactions.
    Georgiou L; Penny J; Nicholls G; Woodhouse N; Blé FX; Naish JH; Hubbard Cristinacce PL
    Invest Radiol; 2018 Sep; 53(9):563-570. PubMed ID: 29771727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative Assessment of Liver Function Using Gadoxetate-Enhanced Magnetic Resonance Imaging: Monitoring Transporter-Mediated Processes in Healthy Volunteers.
    Georgiou L; Penny J; Nicholls G; Woodhouse N; Blé FX; Hubbard Cristinacce PL; Naish JH
    Invest Radiol; 2017 Feb; 52(2):111-119. PubMed ID: 28002117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats.
    Scotcher D; Melillo N; Tadimalla S; Darwich AS; Ziemian S; Ogungbenro K; Schütz G; Sourbron S; Galetin A
    Mol Pharm; 2021 Aug; 18(8):2997-3009. PubMed ID: 34283621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function.
    Karageorgis A; Lenhard SC; Yerby B; Forsgren MF; Liachenko S; Johansson E; Pilling MA; Peterson RA; Yang X; Williams DP; Ungersma SE; Morgan RE; Brouwer KLR; Jucker BM; Hockings PD
    PLoS One; 2018; 13(5):e0197213. PubMed ID: 29771932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid.
    Jia J; Puls D; Oswald S; Jedlitschky G; Kühn JP; Weitschies W; Hosten N; Siegmund W; Keiser M
    Invest Radiol; 2014 Feb; 49(2):78-86. PubMed ID: 24056116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced fibrosis: Correlation between pharmacokinetic parameters at dynamic gadoxetate-enhanced MR imaging and hepatocyte organic anion transporter expression in rat liver.
    Lagadec M; Doblas S; Giraudeau C; Ronot M; Lambert SA; Fasseu M; Paradis V; Moreau R; Pastor CM; Vilgrain V; Daire JL; Van Beers BE
    Radiology; 2015 Feb; 274(2):379-86. PubMed ID: 25289480
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.